FHTX
Foghorn Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$247.77M
P/E Ratio
—
EPS
$-1.17
Beta
2.97
52W High
$6.95
52W Low
$3.27
50-Day MA
$4.72
200-Day MA
$4.96
Dividend Yield
—
Profit Margin
-266.90%
Forward P/E
—
PEG Ratio
—
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $28.22M |
| Gross Profit (TTM) | $-53.88M |
| EBITDA | $-78.02M |
| Operating Margin | -660.00% |
| Return on Equity | -470.40% |
| Return on Assets | -21.00% |
| Revenue/Share (TTM) | $0.44 |
| Book Value | $-1.30 |
| Price-to-Book | 2005.35 |
| Price-to-Sales (TTM) | 8.78 |
| EV/Revenue | 3.76 |
| EV/EBITDA | -1.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -45.10% |
| Shares Outstanding | $58.71M |
| Float | $27.41M |
| % Insiders | 17.94% |
| % Institutions | 76.49% |
Historical Volatility
HV 10-Day
79.54%
HV 20-Day
75.26%
HV 30-Day
72.21%
HV 60-Day
68.28%
HV Rank
51.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($11.44 target)
1
Strong Buy9
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026